IP Library Granted Patent US 7,910,335
Granted Patent B2
US 7,910,335 · App. 11/588,732 · Granted Mar 22, 2011

Methods and compositions for labeling nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,335
App. No.
11/588,732
Granted
Mar 22, 2011
Kind
B2
Abstract

The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. In particular, the methods include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures.

Claims (66)

1. A method of measuring cellular proliferation, comprising steps of:

contacting a cell with an effective amount of a nucleoside analogue that comprises a first reactive unsaturated group such that the nucleoside analogue is incorporated into DNA of the cell;

contacting the cell with a reagent comprising a second reactive unsaturated group attached to a label, such that a [3+2] cycloaddition occurs between the first and second reactive unsaturated groups; and

determining an amount of label incorporated into the DNA to measure cellular proliferation;

wherein the first reactive unsaturated group comprises an alkynyl group and the second reactive unsaturated group comprises an azide or wherein the first reactive unsaturated group comprises an azide group and the second reactive unsaturated group comprises an alkynyl group.

2. A method of measuring cellular proliferation in an organism, comprising steps of:

administering to an organism an effective amount of a nucleoside analogue that comprises a first reactive unsaturated group such that the nucleoside analogue is incorporated into DNA of cells of the organism;

contacting at least one cell of the organism with a reagent comprising a second reactive unsaturated group attached to a label, such that a [3+2] cycloaddition occurs between the first and second reactive unsaturated groups; and

determining an amount of label incorporated into the DNA to measure cellular proliferation in the organism;

wherein the first reactive unsaturated group comprises an alkynyl group and the second reactive unsaturated group comprises an azide or wherein the first reactive unsaturated group comprises an azide group and the second reactive unsaturated group comprises an alkynyl group.

3. The method of claim 1 or 2 , wherein the alkynyl group is an ethynyl group.

4. The method of claim 1 or 2 , wherein the label is directly detectable.

5. The method of claim 4 , wherein the label comprises a fluorescent agent.

6. The method of claim 1 or 2 , wherein the label is indirectly detectable.

7. The method of claim 6 , wherein the label comprises a hapten.

8. The method of claim 1 or 2 , wherein the step of contacting the cell with a reagent is performed in absence of Cu(I), and the reagent further comprises a Cu chelating moiety.

9. The method of claim 1 , wherein the cell is in a multi-well plate.

10. A method for identifying an agent that perturbs cellular proliferation, comprising steps of:

(a) contacting a cell with a test agent;

(b) contacting the cell with an effective amount of a nucleoside analogue that comprises a first reactive unsaturated group such that the nucleoside analogue is incorporated into DNA of the cell;

(c) contacting the cell with a reagent comprising a second reactive unsaturated group attached to a label, such that a [3+2] cycloaddition occurs between the first and second reactive unsaturated groups;

(d) determining an amount of label incorporated into the DNA, wherein the amount of label indicates the extent of cellular proliferation; and

(e) identifying the test agent as an agent that perturbs cellular proliferation if the amount of label measured in step (d) is less than or greater than the amount of label measured in a control application in which the cell is not contacted with the test agent;

wherein the first reactive unsaturated group comprises an alkynyl group and the second reactive unsaturated group comprises an azide or wherein the first reactive unsaturated group comprises an azide group and the second reactive unsaturated group comprises an alkynyl group.

11. The method of claim 10 , wherein step (b) is performed before step (a).

12. The method of claim 10 further comprising the step of identifying the test agent as an agent that induces cellular proliferation if the amount of label measured in step (d) is greater than the amount of label measured in the control application.

13. The method of claim 10 further comprising the step of identifying the test agent as an agent that inhibits cellular proliferation if the amount of label measured in step (d) is less than the amount of label measured in the control application.

14. The method of claim 10 , wherein the alkynyl group is an ethynyl group.

15. The method of claim 10 , wherein the label is directly detectable.

16. The method of claim 15 , wherein the label comprises a fluorescent agent.

17. The method of claim 10 , wherein the label is indirectly detectable.

18. The method of claim 17 , wherein the label comprises a hapten.

19. The method of claim 10 , wherein the step of contacting the cell with a reagent is performed in absence of Cu(I) and the reagent further comprises a Cu chelating moiety.

20. The method of claim 10 , wherein the cell is in a multi-well plate.

21. A method for identifying an agent that perturbs cellular proliferation in an organism, comprising steps of:

(a) exposing an organism to a test agent;

(b) administering to the organism an effective amount of a nucleoside analogue that comprises a first reactive unsaturated group such that the nucleoside analogue is incorporated into DNA of cells of the organism;

(c) contacting at least one cell of the organism with a reagent comprising a second reactive unsaturated group attached to a label, such that a [3+2] cycloaddition occurs between the first and second reactive unsaturated groups;

(d) determining an amount of label incorporated into the DNA, wherein the amount of label indicates the extent of cellular proliferation; and

(e) identifying the test agent as an agent that perturbs cellular proliferation in the organism if the amount of label measured in step (d) is less than or greater than the amount of label measured in a control application in which the organism is not exposed to the test agent;

wherein the first reactive unsaturated group comprises an alkynyl group and the second reactive unsaturated group comprises an azide or wherein the first reactive unsaturated group comprises an azide group and the second reactive unsaturated group comprises an alkynyl group.

22. The method of claim 21 , wherein step (b) is performed before step (a).

23. The method of claim 21 further comprising the step of identifying the test agent as an agent that induces cellular proliferation in the organism if the amount of label measured in step (d) is greater than the amount of label measured in the control application.

24. The method of claim 21 further comprising the step of identifying the test agent as an agent that inhibits cellular proliferation in the organism if the amount of label measured in step (d) is less than the amount of label measured in the control application.

25. The method of claim 21 , wherein the alkynyl group is an ethynyl group.

26. The method of claim 21 , wherein the label is directly detectable.

27. The method of claim 26 wherein the label comprises a fluorescent agent.

28. The method of claim 21 , wherein the label is indirectly detectable.

29. The method of claim 28 , wherein the label comprises a hapten.

30. The method of claim 21 , wherein the step of contacting with a reagent is performed in vitro.

31. The method of claim 1 , wherein the first reactive unsaturated group comprises an alkynyl group and the second reactive unsaturated group comprises an azide group.

32. The method of claim 31 , wherein the alkynyl group is an ethynyl group.

33. The method of claim 2 , wherein the first reactive unsaturated group comprises an alkynyl group and the second reactive unsaturated group comprises an azide group.

34. The method of claim 33 , wherein the alkynyl group is an ethynyl group.

35. The method of claim 10 , wherein the first reactive unsaturated group comprises an alkynyl group and the second reactive unsaturated group comprises an azide group.

36. The method of claim 35 , wherein the alkynyl group is an ethynyl group.

37. The method of claim 21 , wherein the first reactive unsaturated group comprises an alkynyl group and the second reactive unsaturated group comprises an azide group.

38. The method of claim 37 , wherein the alkynyl group is an ethynyl group.

39. The method of claim 1 , wherein the nucleoside analogue is ethynyl-dU.

40. The method of claim 2 , wherein the nucleoside analogue is ethynyl-dU.

41. The method of claim 10 , wherein the nucleoside analogue is ethynyl-dU.

42. The method of claim 21 , wherein the nucleoside analogue is ethynyl-dU.

43. The method of claim 1 , wherein the nucleoside analogue is azido-dU.

44. The method of claim 2 , wherein the nucleoside analogue is azido-dU.

45. The method of claim 10 , wherein the nucleoside analogue is azido-dU.

46. The method of claim 21 , wherein the nucleoside analogue is azido-dU.

Assignments (5)
CONFIRMATORY LICENSE Recorded Nov 8, 2021
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 058830/0724 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO 09452626 PREVIOUSLY RECORDED ON REEL 023882 FRAME 0551. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER SHOULD NOT HAVE BEEN RECORDED AGAINST THIS PATENT APPLICATION NUMBER. Recorded Nov 14, 2014
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 034217/0490 →
MERGER Recorded Feb 3, 2010
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023882/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2007
From: SALIC, ADRIAN; MITCHISON, TIMOTHY J.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 019289/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2006
From: GEE, KYLE R.; AGNEW, BRIAN
To: INVITROGEN CORPORATION
Reel/Frame 018693/0471 →